

Our ref :

Date :



أشارتنا: ٠٠١٧١٩

التاريخ: ١٦-٠٣-٤٦٠

٢٦ / جمادى الثاني / ١٤٣٧ هـ

Fingolimod (Gilenya) - Risks related to the effects on the immune system

Dear Healthcare Professional,

In agreement with the Saudi Food and Drug Authority (SFDA), Novartis would like to inform you of recent product information changes in relation to the immunosuppressive effects of fingolimod (Gilenya) and to take this opportunity to remind you of some important recommendations for use.

Summary

The adverse effects listed below have been reported in patients receiving fingolimod.

- **Basal cell carcinoma**
 - Medical evaluation of the skin before treatment initiation and during treatment is recommended.
- **Progressive multifocal leukoencephalopathy (PML):**
 - Physicians should be alert to the risk of PML. They should inform patients and carers of early symptoms suggestive of PML and instruct them to seek medical advice if such symptoms occur.
 - Before initiating treatment with fingolimod, a baseline MRI should be available (usually within 3 months) as a reference.
 - During routine MRI, physicians should pay close attention to lesions suggestive of PML.
 - If PML is suspected MRI should be performed immediately for diagnostic purposes and treatment with fingolimod should be suspended until PML has been excluded.
- **Other infections with opportunistic pathogens, including infections of the central nervous system**

In the event of infection:

 - Initiation of treatment should be delayed in patients with severe active infection until resolution.
 - Suspension of treatment should be considered if a patient develops a serious infection, and benefit/risk should be carefully considered prior to re-initiation of therapy.
- **Continue following complete blood count (CBC) monitoring requirements**

Further information

Fingolimod is licensed as a disease modifying therapy for the treatment of patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Due to its immunosuppressive effects, fingolimod may predispose to serious adverse reactions. In this respect, the product information of fingolimod will be updated.

- **Basal cell carcinoma**

Cases of basal cell carcinoma (BCC) have been reported in patients receiving fingolimod. Cases were reported from both the clinical trial programme and the post-marketing setting. Therefore, vigilance for skin lesions is warranted and a medical evaluation of the skin is recommended at treatment initiation,

Novartis Consulting AG - Scientific Office

MOC LICENCE NO.3

Riyadh	Jeddah	Dammam	الرياض	جدة	الدمام
P.O.Box 18032	P.O. Box 8640	P.O. Box 6503	ص. ب : ١٦٠٣٢	ص. ب : ٨٦٤٠	ص. ب : ٦٥٠٣
Riyadh 11464	Jeddah 21492	Dammam 31452	الرياض : ١١٤٦٤	جدة : ٢١٤٩٢	الدمام : ٣١٤٥٢
Telephone : 465 8882	Telephone : 669 5666	Telephone : 834 3174	تلفون : ٤٦٥ ٨٨٨٢	تلفون : ٦٦٩ ٥٦٦٦	تلفون : ٨٣٤ ٣١٧٤
Telefax : 464 8127	Telefax : 663 3534	Telefax : 834 4200	تليفاكس : ٤٦٤ ٨١٢٧	تليفاكس : ٦٦٣ ٣٥٣٤	تليفاكس : ٨٣٤ ٤٢٠٠

مكتب شركة نوفارتس كونسولتنغ إي جي المكتب العلمي

ترخيص وزارة التجارة رقم ٣

اشارتنا :

التاريخ :

Our ref :

Date :



after at least one year and then at least yearly taking into consideration clinical judgement. The patient should be referred to a dermatologist if suspicious lesions are detected.

Patients with known active malignancies (including BCC) must not be treated with fingolimod.

• Opportunistic Infections

The immunosuppressive effects of fingolimod may increase the risk of infections involving the CNS, including opportunistic infections such as viral infections (e.g. herpes simplex virus, varicella zoster virus), fungal infections (e.g. cryptococcal meningitis) or bacterial infections (e.g. atypical mycobacterium).

Prescribers are reminded that:

- Initiation of treatment with fingolimod should be delayed in patients with severe active infection until resolution.
- Suspension of fingolimod should be considered if a patient develops a serious infection and benefit-risk should be carefully considered prior to re-initiation of therapy.
- Elimination of fingolimod following discontinuation of therapy may take up to two months and vigilance for infection should therefore be continued throughout this period.

❖ Progressive multifocal leukoencephalopathy (PML)

Cases of PML have been reported during fingolimod treatment. PML is an opportunistic infection caused by JCV which may be fatal or result in severe disability. PML can only occur in the presence of a JCV infection. If JCV testing is undertaken, it should be considered that the influence of lymphopenia on the accuracy of anti-JCV antibody test has not been studied in fingolimod treated patients. It should also be noted that a negative anti JCV antibody test does not preclude the possibility of subsequent JCV infection. Before initiating treatment with fingolimod, a baseline MRI should be available (usually within 3 months) as a reference. During routine MRI (in accordance with national and local recommendations), physicians should pay attention to PML suggestive lesions. MRI may be considered as part of increased vigilance in patients considered at increased risk of PML. If PML is suspected, MRI should be performed immediately for diagnostic purposes and treatment with fingolimod should be suspended until PML has been excluded.

• Lymphoma

Cases of lymphoma have been reported in patients treated with fingolimod.

• Complete blood count monitoring

Finally, healthcare professionals are reminded that a recent (i.e. within 6 months or after discontinuation of prior therapy) complete blood count (CBC) should be available prior to initiation of fingolimod therapy in order to ensure that the effects of the previous therapy on the immune system (i.e. cytopenia) have resolved. Periodic assessments of CBC are also recommended during treatment (i.e. 3 months after starting treatment and at least yearly thereafter), and in case of signs of infection.

Call for reporting

Please report any suspected adverse reactions associated with the use of fingolimod in accordance with the national requirements via:

The National Pharmacovigilance and Drug Safety Center:

Toll free phone: 8002490000

Fax: +966112057662

E-mail: npc.drug@sfd.gov.sa

Or by online: <https://ade.sfd.gov.sa>

Company contact point :

Novartis Consulting AG.

Phone: +996112658100

Mobile: 0508035430

Fax: +966112658107

Email: adverse.events@novartis.com

Yours sincerely,

Malak Alowais

Drug Safety Responsible Deputy



Novartis Consulting AG - Scientific Office

MOC LICENCE NO.3

Riyadh

P.O.Box 16032

Riyadh 11464

Telephone : 465 8882

Telefax : 464 8127

Jeddah

P.O. Box 8640

Jeddah 21492

Telephone : 669 5666

Telefax : 663 3534

Dammam

P.O. Box 6503

Dammam 31452

Telephone : 834 3174

Telefax : 834 4200

الدمام

ص. ب. ٦٥٠٣

الدمام : ٣١٤٥٢

تلفون : ٨٣٤ ٣١٧٤

تليفاكس : ٨٣٤ ٤٢٠٠

جدة

ص. ب. ٨٦٤٠

جدة : ٢١٤٩٢

تلفون : ٦٦٩ ٥٦٦٦

تليفاكس : ٦٦٣ ٣٥٣٤

الرياض

ص. ب. ١٦٠٣٢

الرياض : ١١٤٦٤

تلفون : ٤٦٥ ٨٨٨٢٢

تليفاكس : ٤٦٤ ٨١٢٧

مكتب شركة نوفارتس كونسولتنج إي جي المكتب العلمي

ترخيص وزارة التجارة رقم ٣